James Nininger, MD
Psychiatry · New York, NYNPI 1235298530
Payments from drug & device makers
Across 176 payments — averaging $40.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Lundbeck LLC$765
- Takeda Pharmaceuticals U.S.A., Inc.$684
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$631
- Otsuka America Pharmaceutical, Inc.$625
- Alkermes, Inc.$406
- plus $700 from 4 others
What the payments were for
- Food & beverage$7,09499%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 74 | $3,329 |
| Lundbeck LLC | 28 | $765 |
| Takeda Pharmaceuticals U.S.A., Inc. | 28 | $684 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 17 | $631 |
| Otsuka America Pharmaceutical, Inc. | 5 | $625 |
| Alkermes, Inc. | 7 | $406 |
| Sunovion Pharmaceuticals Inc. | 12 | $304 |
| Teva Pharmaceuticals USA, Inc. | 2 | $152 |
| Johnson & Johnson | 2 | $124 |
| Pfizer | 1 | $120 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$2,325
- LYBALVI$976
- REXULTI$375
- CAPLYTA$268
- ABILIFY MAINTENA$250
- LATUDA$125
- ABILIFY ASIMTUFII$125
- UZEDY$125
- NURTEC ODT$120
- SPRAVATO$119
- TRINTELLIX$107
How this compares
$7,141 in reported general payments places this provider in the 90th percentile of 3,713 psychiatry providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProzacFluoxetine Hcl | 11 | $9,401 |
| Escitalopram Oxalate | 112 | $2,133 |
| Bupropion XlBupropion Hcl | 74 | $1,736 |
| Quetiapine Fumarate | 86 | $1,449 |
| Clonazepam | 108 | $1,417 |
| Mirtazapine | 31 | $1,051 |
| Lorazepam | 73 | $1,021 |
| Trazodone Hcl | 57 | $811 |
| Lamotrigine | 81 | $793 |
| Methylphenidate Hcl | 16 | $761 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 15 | $759 |
| Aripiprazole | 13 | $704 |
| Alprazolam | 78 | $569 |
| Duloxetine Hcl | 25 | $510 |
| Sertraline Hcl | 27 | $390 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in New York
- Michael LiebowitzNew York$7.1M
- Paul EderNew York$2.7M
- Lenard AdlerNew York$1.8M
- Ram ShrivastavaNew York$1.8M
- Jonathan KaneNew York$1.8M
- Eric HollanderNew York$1.4M
- William HapworthNew York$1.3M
- Manish ZinzuvadiaNew York$1.3M
- Jianping ChenNew York$1.2M
- Anthony ZoghbiNew York$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.